TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06658548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise training with resistance exercise
Description: The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
Study: NCT06660719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8203
Description: SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study: NCT06659549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAL-101
Description: Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will apply daily 2 eye drops of Placebo at 5 minutes interval
Study: NCT06029244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EyeControl-Pro
Description: Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
Study: NCT06659159

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric ultrasound
Description: The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed.
Study: NCT06029244

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No intervention
Study: NCT06587334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: SRP alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nd: YAG Laser Assisted SRP
Description: the patients receive SRP combined with Nd: YAG laser
Study: NCT06608550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: short video film
Description: Children will be trained with a short movie to prepare for the endoscopy procedure. The content of the short movie video training will include; introduction of the outpatient clinic, things to be considered before the procedure, preparation for the procedure, introduction of the endoscopy room, introduction of the service to come after endoscopy, issues to be considered after the procedure. The short movie training is expected to last approximately 5 minutes.
Study: NCT06604767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: parainfluenza virus type 3 vaccine (PIV3)
Description: Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: parainfluenza virus type 3 vaccine (PIV3)
Description: Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: parainfluenza virus type 3 vaccine (PIV3)
Description: Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: parainfluenza virus type 3 vaccine (PIV3)
Description: Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV/PIV3 vaccine
Description: Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
Study: NCT05331170

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Research Grade RG-RV
Description: Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
Study: NCT05396833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
Study: NCT06604767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine
Description: Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/hMPV vaccine
Description: Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine 1
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine 2
Description: Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
Study: NCT06660576

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholecystectomy and histochemical analysis of Gallbladder stones
Description: Cholecystectomy and histochemical analysis of Gallbladder stones
Study: NCT05396833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib
Description: Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
Study: NCT06658262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Exercises With Cycling Exercises
Description: Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.

Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi Exercises Alone
Description: Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
Study: NCT05396833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib
Description: Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib
Description: Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib
Description: Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib
Description: Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib
Description: Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
Study: NCT05088876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded withdrawal of regular co-medication with paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol in the dose already used
Study: NCT06458049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Session
Description: On-line educational session-3 modules-1 hour each for a total of 3 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Call
Description: Single Coaching phone call at one month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer
Study: NCT05937425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LungCaNN
Description: The needs of the patients included in the study will be determined with the supportive care needs scale. A training booklet will be given to the patients in the intervention group and they will be informed about the existing or newly formed unsupported care needs, the evaluation of their frequency and severity, and the ability of the patients to call the navigator nurse 24/7 or send an SMS. For interventions that can be applied in line with evidence-based guidelines for unsupported care needs with patients included in the intervention group every week for 12 weeks, a face-to-face navigation will be made by the navigator nurse over the phone and once a month.
Study: NCT05933265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-184
Description: LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-184
Description: LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-184
Description: LP-184 is a small molecule alkylating agent causing tumor cell death through DNA damage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: To evaluate the safety and tolerability of LP-184 as monotherapy and when administered with spironolactone (SP) in subjects with recurrent (IDH) wildtype glioblastoma.
Study: NCT06238479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4101174
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4101174
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4101174
Description: Intravenous
Study: NCT06510322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched capsule not containing any medication
Study: NCT05673486

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PENG Block
Description: With the patient in the supine position, the ultrasound probe is placed on a transverse plane over the anterior superior iliac spine (ASIS). Once the ASIS is identified, the transducer is aligned with the pubic ramus and rotated at approximately 45 degrees, parallel to the inguinal crease. The transducer is then slid medially along this axis until the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), and the psoas tendon is clearly identified, serving as anatomic landmarks.~Sliding the probe distally or gently tilting the caudal will expose the head of the femur. Returning to the initial starting position, a needle is inserted in-plane, from lateral to medial, in the plane between the psoas tendon and the pubic ramus. 100 mg of ropivacaine is then deposited in this plane, lifting the psoas tendon.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal analgesia
Description: Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Description: Multimodal analgesia is administered to patients as follows : 2-3 mg of morphine (2mg if patient's weight \<60kg; 3mg if patient's weight \>60kg) + Paracetamol 1g/8h and Nefopam 20mg/8h. Frequency of morphine administration depends on the assessed pain.
Study: NCT04770233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early ACL reconstruction
Description: ACL reconstruction followed by rehabilitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active rehabilitation
Description: Non-operative treatment with active rehabilitation led by a physiotherapist with optional delayed surgery if indicated.
Study: NCT06519279

Intervention type: DEVICE
Intervention: Opals
Description: Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.

Intervention type: DEVICE
Intervention: Opals
Description: Five Oplas sensors were strategically placed on participants: one on each shin, one on each foot, and one on the lower back.
Study: NCT06661668

Intervention type: DEVICE
Intervention: Gastric pacemaker (Enterra system) implantation
Description: Laparascopic implantation of a gastric pacemaker (Enterra system) for patients with therapy refractive gastroparesis
Study: NCT06660615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIDWIFE-LED CARE
Description: The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
Study: NCT06607497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention using an AI enabled risk communication tool (PERDICT.AI)
Description: Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention using an AI enabled risk communication tool (PERDICT.AI)
Description: Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)
Description: The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
Study: NCT06661928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Papilla preservation flap
Description: Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Widman flap procedure
Description: Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures.
Study: NCT06008418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The LINE Chatbot
Description: The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.